157 related articles for article (PubMed ID: 29468838)
1. Anti-vascular endothelial growth factors treatment of wet age-related macular degeneration: from neurophysiology to cost-effectiveness.
Vottonen P
Acta Ophthalmol; 2018 Feb; 96 Suppl A109():1-46. PubMed ID: 29468838
[No Abstract] [Full Text] [Related]
2. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
Brown GC; Brown MM; Rapuano S; Boyer D
Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective.
van Asten F; Michels CTJ; Hoyng CB; van der Wilt GJ; Klevering BJ; Rovers MM; Grutters JPC
PLoS One; 2018; 13(5):e0197670. PubMed ID: 29772018
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.
Vottonen P; Kankaanpää E
Acta Ophthalmol; 2016 Nov; 94(7):652-656. PubMed ID: 27481048
[TBL] [Abstract][Full Text] [Related]
6. Aflibercept in exudative age related macular degeneration refractory to ranibizumab.
Ruiz Ramos J; Pascual-Camps I; Cuéllar-Monreal MJ; Dolz-Marco R; Fenoll MA; Font-Noguera I; Poveda-Andrés JL; Gallego-Pinazo R
Arch Soc Esp Oftalmol; 2015 Dec; 90(12):566-71. PubMed ID: 26515015
[TBL] [Abstract][Full Text] [Related]
7. Initial improvements when converting eyes with treatment-resistant exudative AMD to aflibercept are substantially diminished after increasing treatment intervals from 4 to 8 weeks.
Jørstad ØK; Faber RT; Moe MC
Acta Ophthalmol; 2015 Sep; 93(6):e510-1. PubMed ID: 25708506
[No Abstract] [Full Text] [Related]
8. Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network.
Jampol LM; Glassman AR; Bressler NM
JAMA Ophthalmol; 2015 Sep; 133(9):983-4. PubMed ID: 26087135
[No Abstract] [Full Text] [Related]
9. Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration.
Shaikh AH; Toussaint BW; Miller DM; Petersen MR; Foster RE; Riemann CD; Hutchins RK; Sisk RA
Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):62-6. PubMed ID: 25559511
[TBL] [Abstract][Full Text] [Related]
10. Experience of New Brunswick ophthalmologists using intravitreal anti-vascular endothelial growth factor.
Giberson M; Taylor V
Can J Ophthalmol; 2015 Oct; 50(5):393-4. PubMed ID: 26455977
[No Abstract] [Full Text] [Related]
11. Effects of intravitreal aflibercept and ranibizumab on retinal vessel diameter measured using fluorescein angiography.
Min JK; Lee S; Park JH; Woo JM; Yang HS
Acta Ophthalmol; 2018 Jun; 96(4):e546-e547. PubMed ID: 29068524
[No Abstract] [Full Text] [Related]
12. [Interest of optical coherence tomography performed immediately before intravitreal injection of anti-VEGF in exudative AMD].
Moyal L; Cohen SY; Pedinielli A; Semoun O; Lalloum F; Jung C; Souied E
J Fr Ophtalmol; 2015 Sep; 38(7):573-9. PubMed ID: 25997681
[TBL] [Abstract][Full Text] [Related]
13. Cost and Selection of Ophthalmic Anti-Vascular Endothelial Growth Factor Agents.
Li E; Greenberg PB; Voruganti I; Krzystolik MG
R I Med J (2013); 2016 May; 99(5):15-7. PubMed ID: 27128510
[TBL] [Abstract][Full Text] [Related]
14. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.
Erie JC; Barkmeier AJ; Hodge DO; Mahr MA
Ophthalmology; 2016 Jun; 123(6):1257-62. PubMed ID: 26976701
[TBL] [Abstract][Full Text] [Related]
15. INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX).
Houston SK; Rayess N; Cohen MN; Ho AC; Regillo CD
Retina; 2015 Sep; 35(9):1757-64. PubMed ID: 26110596
[TBL] [Abstract][Full Text] [Related]
16. Canadian preference and trends survey results for anti-VEGF treatment of macular edema.
Rayat JS; Grewal PS; Whelan J; Tennant MT; Choudhry N
Can J Ophthalmol; 2016 Jun; 51(3):233-7. PubMed ID: 27316276
[No Abstract] [Full Text] [Related]
17. Wet age related macular degeneration management and follow-up.
Alexandru MR; Alexandra NM
Rom J Ophthalmol; 2016; 60(1):9-13. PubMed ID: 27220225
[TBL] [Abstract][Full Text] [Related]
18. NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators.
Vogel RN; Davis DB; Kimura BH; Rathinavelu S; Graves GS; Szabo A; Han DP
Retina; 2017 Feb; 37(2):257-264. PubMed ID: 27429385
[TBL] [Abstract][Full Text] [Related]
19. Switch of anti-vascular growth factor agent from aflibercept to bevacizumab; outcomes in chronic wet age-related macular degeneration.
Granstam E; Sjövall K; Rosén M
Acta Ophthalmol; 2022 Dec; 100(8):e1772-e1773. PubMed ID: 35587775
[No Abstract] [Full Text] [Related]
20. Neovascular Age-Related Macular Degeneration.
Shao J; Choudhary MM; Schachat AP
Dev Ophthalmol; 2016; 55():125-36. PubMed ID: 26501146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
